Julian is the Executive Chair of EKF Diagnostics Holdings plc and Renalytix plc. Under his leadership, EKF has successfully completed multiple fundraisings and acquired and integrated eight businesses across seven countries, growing revenue from zero to over £40 million.
Prior to EKF, Julian served as Group CEO of BBI Holdings plc, where he led a management buyout in 2000, its AIM flotation in 2004, and ultimately the sale of the business to Alere, Inc. (now part of Abbott Laboratories) in 2008 for approximately £85 million.
In recognition of his contributions to the life sciences industry, Julian was awarded an MBE in 2016. He was appointed a Non-Executive Director of the Company on 22 April 2020.
Sir Ian Carruthers holds a number of chair and non-executive board and advisory roles in the public and private sectors. He was previously Chief Executive of NHS South of England, comprising three health bodies: South West, South Central and South East and his career in the National Health Services spans over 40 years. He was awarded the Order of the British Empire for services to health in 1997 and a Knighthood in 2003 for services to the NHS and in 2006 he took over as Interim Chief Executive of NHS England, amongst the largest organisations in the world with over 1.3 million employees and a budget in excess of £100 billion. He has been the lead author on several papers on reviewing and improving the NHS and is seen as an international expert on healthcare systems and service delivery.
He is currently Chancellor of the University of the West of England, and was formerly Chair of Healthcare UK, Chair of the Innovation Health and Wealth Implementation Board, Co-Chair of the Prime Minister’s Challenge on Dementia and Non-Executive Director of Bioquell plc.
Sir Ian Carruthers was appointed as a director of the Company on 19 August 2020 and currently serves as Chair of the Remuneration Ctee.
Sara has leadership experience both financially and operationally with a focus upon developing and commercialising life science products. She was the CEO of LungLife AI a diagnostic company for early stage lung cancer. Prior to that she was with Bruin Biometrics, a LA-based medical device company as EVP Business Operations and previously CFO. In her role at Exosome Diagnostics, a venture-backed personalised medicine company the focus was upon the development of non-invasive liquid biopsy diagnostics in cancer and the company was successfully sold to Bio-Techne Corporation in 2018. She was previously CFO at AusAm Biotechnologies developing diagnostics in kidney disease. Prior to working in the US, she worked for British Telecom in London in business development and strategy. Sara received her B.A. from Lancaster University and she is qualified as a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. She has also qualified with Chartered Institute of Marketing.
Sara was appointed a director of the Company on 19 August 2020.
Aubrey has over 30 years' experience in supporting and advising growth companies, 26 of which have been spent in investment banking and corporate finance. He trained at Salomon Brothers (now Citi) for two years before transitioning to small and mid-cap roles at Panmure Gordon where he spent 12 years(including buyside investment and portfolio company support, as well as early-stage public companies at Durlacher prior to Panmure Gordon’s reverse takeover in April 2005). Aubrey worked at N+1 Singer, which became Singer Capital Markets, from early 2012 to mid-2024, serving as an AIM Qualified Executive and advising Main Market companies, as Sponsor, on their obligations.
Aubrey has extensive experience in deal execution in equity capital markets and M&A, for public companies as well as private, and has focused predominantly on Healthcare and Life Sciences, TMT and other technology-enabled businesses, over the course of his career. He brings a blend of skills from corporate finance to deal-making, as well as a strong track record of effectively guiding clients through reporting cycles, which supports his proposed role as a member of the Audit Committee, as well advising on their wider regulatory and investor obligations including corporate governance, and a member of the Remuneration Committee.
Previous experience also includes strategic consultancy covering growth and investment decision-making, as well as corporate communications, and working in biotech research for ICI Pharmaceuticals.
Dr Gallon is Professor of Medicine and Surgery, Director, Abdominal Organ Transplant Program at the University of Illinois, Chicago. He is an alumnus of the University of Padua Medical School, Italy and Harvard Medical School.
An expert in nephrology and hypertension as well as organ transplantation, Dr. Gallon’s primary research interests include:
With 20 years’ experience in the life sciences industry, focusing largely on nephrology and organ transplantation, Dr. Gallon is excellently placed to provide insight and guidance in the development of Verici’s two lead products, PTRA™ and Tutivia™. He was a collaborator and co-author with Verici’s previous SAB Chair, Dr. Barbara Murphy, in the GoCar study which was foundational in the development of Verici’s products. He has also been a member of the Editorial Board at the journal Nephron since 2019.
Dr. Alexander Wiseman is the Executive Director of Kidney Transplantation at AdventHealth Transplant in Denver Colorado. He completed both his undergraduate and medical school training at Washington University in St. Louis, followed by residency training in Internal Medicine at University of California San Francisco, and completed his nephrology and transplant nephrology fellowships at University of Colorado. He is internationally recognized in education and clinical research, with over 230 invited lectures and over 120 publications, and has directed numerous research and educational programs for the AST, ASN and NKF, most recently serving as Co-Chair of the AST Medical Director Task Force and Medical Directors Forum, as Invited Faculty of the ASN Annual Board Review Course and Update, and as Co-Chair of the National Kidney Foundation Workshop on Delayed Graft Function. He has held directorship positions for kidney transplant programs since 2008, and in his current role at AdventHealth he is active in creating partnerships with nephrologists to provide comprehensive kidney management care delivery. His clinical and research interests include optimization of care delivery for chronic kidney disease, organ allocation and utilization, and novel immunosuppressive and immune monitoring strategies.
Dr. Antony Chang earned his undergraduate biology degree from the Massachusetts Institute of Technology and medical degree from Albany Medical College in upstate New York. Trained in anatomic and clinical pathology at the University of Washington where he completed is renal pathology fellowship with Charlie Alpers. Dr. Chang joined the Department of Pathology at the University of Chicago in 2004 where he is now a professor.
Dr. Chang is Past-President of the Renal Pathology Society (2017) and the Chicago Pathology Society (2011-2013). He has taught more than 35 educational courses for the American Society Clinical Pathology, College of American Pathologists, US & Canadian Academy of Pathology, American Society of Nephrology, American College of Rheumatology, and American Urological Association.
Dr. Chang research interests include the role of B and plasma cells in lupus nephritis and transplant rejection. Dr. Chang is on the editorial board of Archives of Pathology and Laboratory Medicine. Have authored over 100 peer-reviewed papers, reviews, and book chapters, including the kidney chapter for Robbins and Cotran: Pathologic Basis of Disease. Editor of the 3rd edition of the “Diagnostic Pathology: Transplant Pathology” textbook and co-editor for 2nd through 4th editions of “Diagnostic Pathology: Kidney Diseases.”
Aravind Cherukuri is an Assistant Professor of Medicine, Surgery, and Immunology at the University of Pittsburgh and Co‑Director for Clinical Research at the Thomas E. Starzl Transplantation Institute. A physician–scientist specializing in transplant immunology and kidney transplantation, his research focuses on immunobiology of TCMR, cytokine‑expressing B cells, innate allorecognition, and immune biomarkers that predict rejection and graft outcomes.
Dr. Cherukuri has authored more than 40 peer‑reviewed publications, including in Science Translational Medicine, Nature Medicine, and Nature Communications. He is PI or co‑investigator on several NIH-funded studies and has received multiple national and international honors, including Young Investigator Awards from AST and TTS, the NKF Rising Star Award, and the ASCI Young Physician Scientist Award.
He serves as Associate Editor for JCI Insight and Human Immunology and is actively involved in mentoring, teaching, and scientific leadership within the transplant community.
Dr. Emilio Poggio completed medical school at University Del Salvador in Buenos Aires, Argentina, and clinical training in Nephrology and Hypertension at Cleveland Clinic. Dr. Poggio is a transplant nephrologist in the Department of Kidney Medicine at Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of CWRU. He also has a joint appointment with the Transplant Center and the Department of Immunology at the Lerner Research Institute.
Dr. Poggio is interested in the development of tools to risk-stratify transplant subjects and the development of novel non-invasive immune monitoring techniques that permit the clinician to more accurately risk-stratify kidney transplant recipients.
Dr. Flavio Vincenti is a renowned nephrologist and transplant medicine specialist who has been a key figure at the University of California, San Francisco (UCSF) since 1975. He arrived at UCSF for a fellowship in transplant nephrology and soon joined the kidney transplant team, launching a career that would span nearly five decades of leadership in kidney and pancreas transplantation. Board‑certified in internal medicine and nephrology, Dr. Vincenti is a Clinical Professor of Medicine and Surgery and holds an endowed chair in kidney transplantation at UCSF.
Throughout his career, Dr. Vincenti has been a pioneering investigator in transplant immunology. He co‑authored influential early work in the New England Journal of Medicine on the beneficial effects of blood transfusion in kidney transplantation and has led pivotal research on anti–interleukin‑2 receptor monoclonal antibodies to reduce rejection risk. His research portfolio includes extensive writing on transplant complications and strong advocacy for minimizing immunosuppressive therapy when possible. Additionally, he serves on editorial boards for major journals, including the American Journal of Kidney Diseases and Graft, and plays a central role in the Immune Tolerance Network as co‑leader of its kidney section.
A respected leader in the global transplant community, Dr. Vincenti is a longtime member of the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology, and The Transplantation Society. He continues to care for patients through UCSF’s Kidney Transplant Center, where he specializes in kidney transplantation, pancreas transplantation, and the care of living kidney donors. His enduring commitment to clinical innovation, mentorship, and improving transplant outcomes has made him one of the field’s most influential physician‑scientists.
Dr. Henry B. Randall is a distinguished transplant surgeon and healthcare executive serving as Executive Director of the SSM Health Center for Abdominal Transplantation and Division Chief and Surgical Director of Kidney Transplant Programs. He is also a Professor of Surgery and Adjunct Instructor at Carnegie Mellon University’s Heinz College.
Board‑certified in General Surgery and a Fellow of ACS, ASTS, and AST, Dr. Randall completed surgical and transplant training at the University of California, San Francisco, and holds an MBA from the University of Missouri with a focus in accounting and finance.
Dr. Randall is President‑Elect of the American Society of Transplant Surgeons and serves on the Boards of SSM Health Foundation, MidAmerica Transplantation, Zig Therapeutics, and Verici Dx, LLC. He is widely published, an Associate Editor for Progress in Transplantation, and an active reviewer for leading journals.
His funded research centers on T regulatory cells in ischemia–reperfusion injury and the application of AI and machine learning in transplantation. A dedicated mentor, Dr. Randall, supports learners and early‑career clinicians, with a strong commitment to advancing opportunities for underrepresented groups in medicine.
Dr. Jesse Schold is currently a tenured Professor in the Departments of Surgery and Epidemiology at University of Colorado. He is Director of the Center for Outcomes Research and Policy in the Department of Surgery in the Division of Transplantation. He received undergraduate training at Emory University, two master’s degrees from North Carolina State University and a Doctorate from University of Florida. Dr. Schold’s research interests include health services research, healthcare inequities, quality analytics and statistical and epidemiological methods. Dr. Schold has authored >400 peer-reviewed scientific publications, has numerous grants and committee roles in the field of transplantation including the current Secretary of the American Society of Transplantation and chair of the OPTN Data Advisory Committee and given >200 invited national and international lectures.
Dr. Maarten Naesens is a transplant nephrologist at the University Hospitals Leuven. Next to the clinical duties, he performs translational research at the Department of Microbiology, Immunology and Transplantation at the KU Leuven, focusing on risk factors, diagnosis, and impact of kidney transplant rejection. From 2024 onwards, he is Associate Editor of Kidney International, the official journal of the International Society of Nephrology (ISN) and is involved in the organization of the European Society of Organ Transplantation (ESOT) and Banff congresses. He has published more than 300 peer-reviewed articles in the field of kidney transplantation.
Dr. Madhav C. Menon is the director of research in Kidney transplantation at Yale and a physician scientist focusing on translational studies to understand how donor- and recipient- genetics influence the development of long-term allograft fibrosis and graft failure – major issues in transplantation. We have had success in translating bench-top discoveries obtained from mouse models to bedside biomarker diagnostics and therapeutics. Our group has developed extensive experience with translational studies in humans using biopsy material, tissue and blood RNA studies, genotyping assays, PBMC flow cytometric evaluations, and morphometry in kidney biopsies. Our work now extends to human randomized trials and multi-center genomic consortia integrating deep phenotyping and computational genomics. With continuous extramural support, our group has had high-impact publications in JCI, JASN, Kidney International, Nature Communications, Lancet, Nature and Nature Medicine, with national/international recognition, and leadership roles in NIH study sections and national/international transplant societies.
Dr. Neeraj Singh is a Transplant Nephrologist, Professor of Internal Medicine, and Medical Director of Kidney and Pancreas Transplant Program at the Robert Wood Johnson University /Rutgers Health in New Brunswick, NJ. Prior to joining Rutgers Health, he served as the Medical Director of Kidney and Pancreas Transplant Program as well as the Academic Chair and Program Director of Internal Medicine Residency at Willis Knighton Health in Shreveport, Louisiana for 13 years. Besides his clinical and administrative responsibilities, Dr. Singh participates in clinical research, as well as in training and education of medical students, residents, and fellows.
Dr. Singh received his medical degree from All India Institute of Medical Sciences, New Delhi, India. Subsequently, he completed a residency in internal medicine followed by a fellowship in nephrology at the State University of New York at Buffalo. He completed a transplant medicine fellowship at the University of Wisconsin.
Dr. Singh is actively involved on several committees at the national level. He serves on the Organ Procurement Transplantation Network (OPTN) Pancreas Committee. He is the Vice-Chair of the American Society of Nephrology (ASN)-American Society of Transplantation (AST) Joint Task Force for Accreditation Council for Graduate Medical Education (ACGME) Accreditation of Transplant Nephrology, past Chair of the American Society of Transplantation (AST) Kidney Pancreas Community of Practice (KPCOP), member-at-large of the AST Medical Directors Committee and the AST Cutting Edge in Organ Transplantation (CEOT) committee.
Dr. Oriol Bestard graduated at Barcelona University medical school (Barcelona, Spain). He subsequently started the Residency in Nephrology at Bellvitge University Hospital. Afterwards, he completed his PhD in Transplant Immunology at Charité University of Medicine (Berlin, Germany) and completed a post-doctoral fellowship at the Multiorgan Transplant Research Laboratory at the University of California San Francisco (UCSF, US). In 2017, he became head of the Kidney transplant program at Bellvitge University Hospital (Barcelona, Spain) and associate professor of Medicine at the University of Barcelona. Since 2021, he is chief of the Nephrology department at Vall d’Hebron University Hospital (Barcelona, Spain) and leads a translational research laboratory at Vall d’Hebron Institute of Research (VHIR), which mainly focuses on Transplant Immunology.
Dr. Paolo Cravedi is an Associate Professor in the Division of Nephrology in the Department of Medicine and the Director of the Translational Transplant Research Center (TTRC). Dr. Cravedi is a scientist physician with a strong interest in kidney transplantation and autoimmune glomerular diseases. His initial studies have contributed to defining the organ allocation system currently used in many countries around the world. Dr. Cravedi was involved in the design and implementation of the first mechanistic clinical studies testing the safety/efficacy profile of B cell depletion in subjects with membranous nephropathy or focal segmental glomerulosclerosis (FSGS).
Dr. Cravedi joined Icahn School of Medicine at Mount Sinai, in 2011, where he started working on the effects of complement and erythropoietin in adaptive immune response. He is interested in implementing new technologies to study alloimmune responses and, more recently, his work has been testing the immune effects of fasting in transplantation.
Dr. Philip O’Connell completed his undergraduate degree at University of New South Wales and his PhD in experimental transplantation at the University of Melbourne. He went on to complete a postdoctoral research fellowship in transplant immunology at Harvard Medical School. Dr. O’Connell is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Australian Academy of Health and Medical Sciences.
Dr. O'Connell is adjunct Professor in the Faculty of Medicine and Health, University of Sydney. Recently he was appointed the Executive Director of the Westmead Institute for Medical Research and is the Director of the Centre for Transplant and Renal Research. He is a trained nephrologist and formerly was the Director of Transplant Medicine and the Clinical Islet Transplant Program at Westmead Hospital. He is also past President of The Transplantation Society. He has previously served as President of the Transplantation Society of Australia and New Zealand; Chairman, Program Committee of the World Congress of the Transplantation Society; Councilor, The Transplantation Society.
Dr. O’Connell established Australia’s first successful clinical islet transplant program and has been involved in research in developing biomarkers for transplantation and precision medicine. He is internationally acknowledged as a pioneer in the fields of islet and kidney transplantation and has been instrumental in developing an effective procedure to transplant pancreatic islets into patients living with type 1 diabetes.
Dr. Prince Mohan Anand is a board-certified transplant nephrologist and serves as Director of Transplant Services and Program Medical Director at the MUSC Health Transplant Program in the Mid-Carolinas. He completed his medical training at the Medical University of Pleven, Bulgaria, followed by Internal Medicine residency and Chief Residency at NewYork-Presbyterian Queens / Weill Cornell Medicine, and General Nephrology and Renal/Pancreas Transplant Fellowships at Columbia University Medical Center.
Dr. Anand is a Fellow of the American College of Physicians, American Society of Transplantation and the American Society of Nephrology. His clinical and research interests include transplant public policy, organ utilization, Renal genetics, recurrent GN in transplant and long-term care of kidney transplant recipients. He is dedicated to advancing transplant medicine through patient care, education, and leadership.
Dr. Rainer Oberbauer is a Professor of Medicine and Director of the Department of Nephrology & Dialysis and Transplant Medicine at the Medical University of Vienna, Vienna, AUSTRIA. Dr. Oberbauer received his MD from the University of Vienna, Austria in 1990 and his MSc in Epidemiology from the Harvard School of Public Health, the USA in 2005. He completed his fellowship in nephrology at the Universities of Vienna and Stanford, became Assistant Professor of Medicine in Vienna in 1996 and advanced to Associate Professor in 1999. In 2006 he was promoted to Director of the Renal Department of the Elisabethinen Hospital, Linz, Austria and 2014 to Director of the Department for Nephrology and Dialysis, Internal Medicine III, Medical University of Vienna.
Dr. Oberbauer has a longstanding clinical and scientific interest in renal transplantation, and he has published numerous experimental as well as clinical papers in this field. He is a member of many international transplant societies, past chair of EKITA and is EIC of Transplant Int’, Associate Editor of NDT’ and on the editorial board of a number of other major international transplant journals. He has also received several academic awards for his scientific papers, which mainly focus on genetic and clinical epidemiology and new immunosuppressive strategies following renal transplantation.
Dr. Roslyn Bernstein Mannon is a Professor of Internal Medicine, and Professor of Pathology, Microbiology, and Immunology at the University of Nebraska Medical Center, Vice-Chair for Research for the Department of Internal Medicine and Associate Chief of Research in the Division of Nephrology. A Duke-trained nephrologist, Dr. Mannon is a translational investigator focused on late kidney allograft outcomes. She has published over 250 peer-reviewed publications on chronic allograft failure and post-transplant complications and therapeutics.
Dr. Mannon is a past president of the American Society of Transplantation and is a Deputy Editor of the American Journal of Transplantation. She is a Trustee of the Banff Foundation for Allograft Pathology, and Medical Director of the Scientific Registry of Transplant Recipients. She has excelled in clinical and translational science and has a lengthy history of advocacy for transplant recipients, being instrumental in the development of the Transplant Therapeutic Consortium, a private-public partnership with FDA to develop new clinical trial endpoints to invigorate the transplant therapeutic pipeline. Dr. Mannon achievements have been recognized by the American Society of Transplantation’s Senior Achievement Award in Clinical Transplantation, the American Association of Kidney Patients Medal of Excellence, and the 2026 National Kidney Foundation Award for Transplant Excellence.
Dr. Weija Zhang received his Ph.D. in Immunology from Albert Einstein College of Medicine and an M.S. in Computer Science from the City University of New York. He is a Professor in the Renal Division of the Department of Medicine and Co-Lead of Bioinformatics at the Data Science Institute at Albert Einstein College of Medicine. Prior to joining Einstein, he was a Professor in the Renal Division of the Department of Medicine at the Icahn School of Medicine at Mount Sinai.
Dr. Zhang has extensive expertise in the analysis of high-throughput genomic data, including gene expression profiling, copy number variation, and single-nucleotide polymorphisms. His research focuses on translational and clinical studies in kidney transplantation, integrating advanced genomic technologies (microarray and next-generation sequencing) with AI- and deep learning–based computational approaches to improve transplant outcomes and organ utilization.
Dr. Zahraa Hajjiri is an Associate Professor of Medicine and transplant nephrologist at the University of Illinois Chicago. She serves as UNOS Medical Director of the Kidney Transplant Program and Director of Transplant Clinics. Her clinical and research work focuses on improving outcomes in kidney transplantation, with particular emphasis on rejection diagnostics, biomarker development, delayed graft function, and optimizing care for high-risk transplant populations. Dr. Hajjiri has led and contributed to multiple clinical and translational studies involving gene expression profiling and donor-derived cell-free DNA, and her work has been presented at major national and international transplant meetings. She is deeply committed to education and mentorship, having trained numerous transplant fellows and contributed extensively to transplant nephrology education. She completed her residency in Internal Medicine at Henry Ford Health System/Wayne State University and went on to complete advanced fellowships in Nephrology and Transplant Nephrology at the University of Massachusetts and the University of Illinois Chicago.
